The DOI matches its Crossref record; 34 of the 37 references it cites were found in a registry or an index.
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Open accessAbstract
Background Metastatic DNA mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) colorectal cancer has a poor prognosis after treatment with conventional chemotherapy and exhibits high levels of tumour neoantigens, tumour-infiltrating lymphocytes, and checkpoint regulators. All of these features are associated with the response to PD-1 blockade in other tumour types. Therefore, we aimed to study nivolumab, a PD-1 immune checkpoint inhibitor, in patients with dMMR/MSI-H metastatic colorectal cancer.Methods In this ongoing, multicentre, open-label, phase 2 trial, we enrolled adults (aged ≥18 years) with histologically confirmed recurrent or metastatic colorectal cancer locally assessed as dMMR/MSI-H from 31 sites (academic centres and hospitals) in eight countries (Australia, Belgium, Canada, France, Ireland, Italy, Spain, and the USA). Eligible patients had progressed on or after, or been intolerant of, at least one previous line of treatment, including a fluoropyrimidine and oxaliplatin or irinotecan. Patients were given 3 mg/kg nivolumab every 2 weeks until disease progression, death, unacceptable toxic effects, or withdrawal from study. The primary endpoint was investigator-assessed objective response as per Response Evaluation Criteria in Solid Tumors (version 1.1). All patients who received at least one dose of study drug were included in all analyses. This trial is registered with ClinicalTrials.gov, number NCT02060188.Findings Of the 74 patients who were enrolled between March 12, 2014, and March 16, 2016, 40 (54%) had received three or more previous treatments. At a median follow-up of 12·0 months (IQR 8·6-18·0), 23 (31·1%, 95% CI 20·8-42·9) of 74 patients achieved an investigator-assessed objective response and 51 (69%, 57-79) patients had disease control for 12 weeks or longer. Median duration of response was not yet reached; all responders were alive, and eight had responses lasting 12 months or longer (Kaplan-Meier 12-month estimate 86%, 95% CI 62-95). The most common grade 3 or 4 drug-related adverse events were increased concentrations of lipase (six [8%]) and amylase (two [3%]). 23 (31%) patients died during the study; none of these deaths were deemed to be treatment related by the investigator.Interpretation Nivolumab provided durable responses and disease control in pre-treated patients with dMMR/MSI-H metastatic colorectal cancer, and could be a new treatment option for these patients.Funding Bristol-Myers Squibb.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Response rates range from 15 to 30% (in most solid tumors) to 45–60% (in melanoma and MSI-H tumors).”
From Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors (2019) · cites this paper as [8]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredIn the citing paper
“Initial results demonstrated a 31% objective response rate and 69% demonstrated at least 12 weeks of stable disease [78].”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [78]
In the citing paper
“The Checkmate-142 phase II study demonstrated the effectiveness of nivolumab in previously treated MSI-H mCRC patients [84].”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [84]
In the citing paper
“Upon examining the subgroup analysis of this study, it was observed that patients without RAS or BRAF mutations achieved a 41% objective response rate with nivolumab. In comparison, the rate was 27% in RAS mutant patients.”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [84]
In the citing paper
“Additionally, the efficacy of ICIs in phase II studies with dMMR/MSI and BRAFV600E tumors versus dMMR/MSI and BRAF wild type was similar [53,54,55,56].”
From Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy (2024) · cites this paper as [54]
In the citing paper
“Recently, a combination of nivolumab and ipilimumab, a CTLA-4 inhibitor, gained approval from the FDA for the treatment of previously treated MSI-H/dMMR mCRC [54,131].”
From Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy (2024) · cites this paper as [54]
In the citing paper
“Nivolumab, an anti-PD1 monoclonal antibody (moAb), has been utilized since 1 August 2017, for MSI-H/dMMR mCRC, as evidenced by the CheckMate 142 study [54].”
From Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy (2024) · cites this paper as [54]
In the citing paper
“The CHECKMATE 142 study reported that Nivolumab could provide a durable response in patients with dMMR/MSI-H metastatic colorectal cancer, proposing Nivolumab as a new treatment option in these patients [117].”
From Immune Checkpoint Inhibitors in Cancer Therapy (2022) · cites this paper as [117]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101
Interpreting the significance of changes in health-related quality-of-life scores.
Osoba, D., Rodrigues, G., Myles, J., Zee, B. C.-Y., & Pater, J. L. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.139 · Cited by 3,016
Brahmer, J. R., Drake, C. G., WOLLNER, I. S., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,967
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895
Self-citationDe Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591
Cited by
Sorted by citations
Items 901–1,000 of 1,005
Chen, X., Gao, S., Wang, X., Guo, M., Cui, Y., Chen, Z., Liu, Y., & Wang, Y. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101583 · Cited by 29
Meireson, A., Chevolet, I., Hulstaert, E., Ferdinande, L., Ost, P., Geboes, K. P., Man, M. D., de Putte, D. V., Verset, L., Krüse, V., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25393 · Cited by 29
Zhu, Y., Zhao, F., Li, Z., & Yu, J. (2018) · Cancer Management and Research · doi:10.2147/cmar.s167400 · Cited by 29
Strategies for Predicting Response to Checkpoint Inhibitors
Zappasodi, R., Wolchok, J. D., & Merghoub, T. (2018) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-018-0471-9 · Cited by 29
Aparicio, T., Canouï‐Poitrine, F., Caillet, P., François, É., Cudennec, T., Carola, É., Albrand, G., Bouvier, A., Petri, C., Couturier, B., et al. (2020) · Digestive and Liver Disease · doi:10.1016/j.dld.2019.12.145 · Cited by 29
Damato, A., Iachetta, F., Antonuzzo, L., Nasti, G., Bergamo, F., Bordonaro, R., Maiello, E., Zaniboni, A., Tonini, G., Romagnani, A., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07268-4 · Cited by 32
Mihăilă, R. I., Gheorghe, A. S., Zob, D., & Stănculeanu, D. L. (2024) · Biomedicines · doi:10.3390/biomedicines12092146 · Cited by 28
Abken, H. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01062-y · Cited by 32
Gray, P. N., Tsai, P. C., Chen, D., Wu, S., Hoo, J., Mu, W., Li, B., Vuong, H., Lu, H., Batth, N., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24854 · Cited by 30
Targeting PD-L1 Protein: Translation, Modification and Transport
Wei, R., Guo, L., Wang, Q., Miao, J., Kwok, H. F., & Lin, Y. (2018) · Current Protein and Peptide Science · doi:10.2174/1389203719666180928105632 · Cited by 28
Selecting treatment options in refractory metastatic colorectal cancer
Byrne, M. M., & Saif, M. W. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s194605 · Cited by 28
Pietrantonio, F., Randon, G., Romagnoli, D., Donato, S. D., Benelli, M., & de Braud, F. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.101935 · Cited by 29
Montés, A. F., Grávalos, C., Pericay, C., Safont, M. J., Benavides, M., Élez, E., Alfonso, P. G., García-Paredes, B., Carrato, A., & Aranda, E. (2020) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2020.04.003 · Cited by 28
Current Treatments of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitors—2020 Update
Jung, G., Benítez‐Ribas, D., Sánchez, A., & Balaguer, F. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113520 · Cited by 28
Woelber, L. L., Mathey, S., Prieske, K., Kuerti, S., Hillen, C., Burandt, E., Coym, A., Müller, V., Schmalfeldt, B., & Jaeger, A. (2020) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504020x16076861118243 · Cited by 28
Sacdalan, D. B., & Lucero, J. A. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s278089 · Cited by 28
Portenkirchner, C., Kienle, P., & Horisberger, K. (2021) · Pharmaceuticals · doi:10.3390/ph14040367 · Cited by 29
Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors and PROTAC-based degraders for cancer therapy
Tang, K., Wang, B., Yu, B., & Liu, H. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113967 · Cited by 28
Vuletić, A. M., Martinović, K. M., Miletić, N. T., Zoidakis, J., Castellvı́-Bel, S., & Cavic, M. R. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.750022 · Cited by 26
Cone, E. B., Haeuser, L., Reese, S. W., Marchese, M., Nguyen, D., Nabi, J., Chou, W. H., Noldus, J., McKay, R. R., Kilbridge, K. L., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0272022 · Cited by 28
Clinical prospects of WRN inhibition as a treatment for MSI tumours
Morales-Juarez, D. A., & Jackson, S. P. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00319-y · Cited by 27
Nasca, V., Barretta, F., Corti, F., Lonardi, S., Niger, M., Élez, E., Fakih, M., Jayachandran, P., Shah, A. T., Salati, M., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005493 · Cited by 29
Self-citationYi, J., Xue, J., Yang, L., Xia, L., & He, W. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1094189 · Cited by 29
Shi, W., Zhang, F., Chen, X., Wang, S., Zhang, H., Yang, Z., Wang, G., Zheng, Y., Han, Y., Sun, Y., et al. (2022) · Cancer Science · doi:10.1111/cas.15360 · Cited by 26
Immune microenvironment and lymph node yield in colorectal cancer
Lee, S., Pankaj, A., Neyaz, A., Ono, Y., Rickelt, S., Ferrone, C. R., Ting, D. T., Patil, D. T., Yilmaz, Ö. H., Berger, D. L., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02372-1 · Cited by 27
Current status and prospect of immunotherapy for colorectal cancer
Yang, W., Zheng, H., Lv, W., & Zhu, Y. (2023) · International Journal of Colorectal Disease · doi:10.1007/s00384-023-04553-z · Cited by 28
Albertí‐Valls, M., Olave, S., Olomí, A., Macià, A., & Eritja, N. (2024) · Cancers · doi:10.3390/cancers16233918 · Cited by 28
Outcomes of Chemotherapy for Microsatellite Instable–High Metastatic Colorectal Cancers
Shulman, K., Barnett‐Griness, O., Friedman, V., Greenson, J. K., Gruber, S. B., Lejbkowicz, F., & Rennert, G. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00253 · Cited by 28
Pathological and Molecular Characteristics of Colorectal Cancer with Brain Metastases
Roussille, P., Tachon, G., Villalva, C., Milin, S., Frouin, É., Godet, J., Berger, A., Emambux, S., Petropoulos, C., Wager, M., et al. (2018) · Cancers · doi:10.3390/cancers10120504 · Cited by 27
Pang, S.-W., Awi, N. J., Armon, S., Lim, W. W.-D., Low, J. S.-H., Peh, K.-B., Peh, S., & Teow, S. (2019) · Diagnostics · doi:10.3390/diagnostics10010009 · Cited by 28
Luo, P., Deng, S., Ye, H., Yu, X., Deng, Q., Zhang, Y., Jiang, L., Li, J., Yu, Y., & Han, W. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110232 · Cited by 27
Garcia‐Vicién, G., Mezheyeuski, A., Bañuls, M., Ruiz-Roig, N., & Mollevı́, D. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041544 · Cited by 29
Vasiliadou, I., Breik, O., Baker, H., Leslie, I., Sim, V., Hegarty, G., Michaelidou, A., Nathan, K., Hartley, A. G. J., Good, J. S., et al. (2021) · Cancers · doi:10.3390/cancers13061413 · Cited by 27
Azcue, P., Encı́o, I., Setas, D. G., Suárez, J., Galbete, A., Mercado, M., Vera, R., & Dorronsoro, M. L. G. (2021) · Cancers · doi:10.3390/cancers13081943 · Cited by 28
Yu, F., Makrigiorgos, A., Leong, K. W., & Makrigiorgos, G. M. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.08.037 · Cited by 28
PKCλ/ι inhibition activates an ULK2-mediated interferon response to repress tumorigenesis
Linares, J. F., Zhang, X., Martínez-Ordóñez, A., Durán, Á., Kinoshita, H., Kasashima, H., Nakanishi, N., Nakanishi, Y., Carelli, R., Cappelli, L. V., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.08.039 · Cited by 28
Cai, C., Peng, Y., Shen, E., Wan, R., Gao, L., Gao, Y., Zhou, Y., Huang, Q., Chen, Y., Liu, P., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103866 · Cited by 28
BRAF-mutated colorectal adenocarcinomas: Pathological heterogeneity and clinical implications
Angerilli, V., Sabella, G., Centonze, G., Lonardi, S., Bergamo, F., Mangogna, A., Pietrantonio, F., Fassan, M., & Milione, M. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103647 · Cited by 27
Self-citationFelip, E., Moreno, V., Morgensztern, D., Curigliano, G., Rutkowski, P. L., Trigo, J. M., Calvo, A., Kowalski, D. M., Cortinovis, D. L., Plummer, R., et al. (2022) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-022-04414-6 · Cited by 25
Organ preservation in rectal cancer: review of contemporary management
Fleming, C., Vendrely, V., Rullier, É., & Denost, Q. (2022) · British journal of surgery · doi:10.1093/bjs/znac140 · Cited by 27
The Multi-Dimensional Biomarker Landscape in Cancer Immunotherapy
Lee, J. Y., Kannan, B., Lim, B. Y., Li, Z., Lim, A. H., Loh, J. W., Ko, T. K., Ng, C. C. Y., & Chan, J. Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147839 · Cited by 29
Wang, R., Lian, J., Wang, X., Pang, X., Xu, B., Tang, S., Shao, J., & Lu, H. (2022) · Biomolecules and Biomedicine · doi:10.17305/bjbms.2022.8286 · Cited by 27
Hereditary Colorectal Cancer Syndromes: Molecular Genetics and Precision Medicine
Chen, L., Ye, L., & Hu, B. (2022) · Biomedicines · doi:10.3390/biomedicines10123207 · Cited by 27
Olguín, J. E., Mendoza-Rodríguez, M., Sánchez-Barrera, C. Á., & Terrazas, L. I. (2023) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v15.i2.251 · Cited by 30
Evaluating mismatch repair deficiency in colorectal cancer biopsy specimens
Grillo, F., Paudice, M., Gambella, A., Bozzano, S., Sciallero, S., Puccini, A., Lastraioli, S., Dono, M., Parente, P., Vanoli, A., et al. (2023) · Histochemistry and Cell Biology · doi:10.1007/s00418-023-02202-8 · Cited by 27
Dingenen, L. V., Segers, C., Wouters, S., Mysara, M., Leys, N., Kumar‐Singh, S., Malhotra‐Kumar, S., & Houdt, R. V. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1298264 · Cited by 29
Fusobacterium nucleatum carcinogenesis and drug delivery interventions
Chen, Z., & Huang, L. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115319 · Cited by 27
Hypermutated Tumors and Immune Checkpoint Inhibition
Ciombor, K. K., & Goldberg, R. M. (2018) · Drugs · doi:10.1007/s40265-018-0863-0 · Cited by 27
Peritoneal Metastases in Colorectal Cancer: Biology and Barriers
Xue, L., Hyman, N., Turaga, K. K., & Eng, O. S. (2019) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-019-04441-4 · Cited by 29
Expert opinions on immunotherapy for patients with colorectal cancer
Wang, F., Wang, Z., Chen, G., Luo, H., Zhang, D., Qiu, M., Wang, D., Pan, Z., Shen, L., Li, J., et al. (2020) · 癌症：英文版 · doi:10.1002/cac2.12095 · Cited by 27
Shields, N. J., Peyroux, E. M., Ferguson, A. L., Steain, M. C., Neumann, S., & Young, S. L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1152035 · Cited by 31
Yu, J., Liao, L., Xiao, B., Zhang, X., Wu, A., Cheng, Y., Tang, J., Wu, J., Kong, L.-H., Han, K., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.7096 · Cited by 27
Approach to evaluating tumor mutational burden in routine clinical practice
Truesdell, J., Miller, V. A., & Fabrizio, D. A. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.10.10 · Cited by 29
Cytoreduction and hyperthermic intraperitoneal chemotherapy in metastatic colorectal cancer
Eng, O. S., & Turaga, K. K. (2019) · Journal of Surgical Oncology · doi:10.1002/jso.25438 · Cited by 26
Kato, K., Doki, Y., Ura, T., Hamamoto, Y., Kojima, T., Tsushima, T., Hironaka, S., Hara, H., Kudo, T., Iwasa, S., et al. (2020) · Cancer Science · doi:10.1111/cas.14380 · Cited by 26
Caracciolo, D., Riillo, C., Arbitrio, M., Martino, M. T. D., Tagliaferri, P., & Tassone, P. (2020) · International Journal of Cancer · doi:10.1002/ijc.33038 · Cited by 29
An update on the use of immunotherapy in patients with colorectal cancer
Nguyen, M., Smith, S. T., Lam, M., Liow, E. C. H., Davies, A., Prenen, H., & Segelov, E. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2021.1845141 · Cited by 28
Pembrolizumab in unresectable or metastatic MSI-high colorectal cancer: safety and efficacy
Roth, M., & Das, S. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1851201 · Cited by 28
Wong, S. K., Beckermann, K. E., Johnson, D. B., & Das, S. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1921140 · Cited by 28
Role of kynurenine in promoting the generation of exhausted CD8+ T cells in colorectal cancer.
Wu, D., & Zhu, Y. (2021) · PubMed · Cited by 26
Current Advances and Trends in KRAS Targeted Therapies for Colorectal Cancer
Teo, M. Y. M., Fong, J. Y., Lim, W. M., & In, L. L. A. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0248 · Cited by 28
Hyung, J., Cho, E. J., Kim, J., Kim, J. H., Kim, J. E., Hong, Y. S., Kim, T. W., Sung, C. O., & Kim, S. Y. (2022) · Cancer Research and Treatment · doi:10.4143/crt.2021.1133 · Cited by 26
Yang, Z., Zhang, X., Zhang, J., Gao, J., Bai, Z., Deng, W., Chen, G., An, Y., Liu, Y., Wei, Q., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-09554-9 · Cited by 26
Román, M. S., Torres-Jiménez, J., Pozas, J., Esteban-Villarrubia, J., Albarrán, V., Ballesteros, P. Á., Chamorro-Pérez, J., Rodriguez, D. I. R., Orejana, I., Martínez-Delfrade, Í., et al. (2023) · Cancers · doi:10.3390/cancers15030863 · Cited by 29
ImmuneMirror: A machine learning-based integrative pipeline and web server for neoantigen prediction
Chuwdhury, G. S., Guo, Y., Chiang, C., Lam, K. O., Kam, N., Liu, Z., & Dai, W. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbae024 · Cited by 27
Goel, G. (2018) · Cancer Management and Research · doi:10.2147/cmar.s162967 · Cited by 26
Das, S., Allen, A., & Berlin, J. D. (2020) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2020.02.006 · Cited by 26
Gallois, C., Bergen, E. S., Auclin, É., Pernot, S., Higué, J., Trouilloud, I., Touchefeu, Y., Turpin, A., Mazard, T., Bianchi, A. S., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103696 · Cited by 25
Yu, Y., Yin, H., Wu, B., Zhao, W., Wang, Y., Aili, A., Yang, M., Yu, Q., & Yuan, X. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-024-01097-4 · Cited by 28
Colorectal Cancer at the Crossroads: The Good, the Bad, and the Future of Platinum-Based Drugs
Kee, J. X., Yau, J. N. N., Muthuramalingam, R. P. K., Wang, X., Chng, W. H., Lopez‐Sanchez, A., Tay, K. K. W., Deng, L., Gibson, D., Bertrand, H. C., et al. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.5c00041 · Cited by 29
Maximising clinical benefit with adequate patient management beyond the second line in mCRC
Argilés, G., Arnold, D., Prager, G. W., Sobrero, A. F., & Cutsem, E. V. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000495 · Cited by 25
Immunotherapeutic Approaches for the Treatment of Colorectal Cancer
Вячеславовна, А. Е., Gelm, Y. V., Пасова, И. А., & Bazhin, A. V. (2019) · Biochemistry (Moscow) · doi:10.1134/s0006297919070046 · Cited by 26
Narasimhan, V., Britto, M. M., Pham, T. D., Warrier, S. K., Naik, A., Lynch, A. C., Michael, M., Tie, J., Ramsay, R. G., & Heriot, A. G. (2019) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000001456 · Cited by 25
Gut microbiota and cancer immunotherapy: prognostic and therapeutic implications
Güven, D. C., Aktaş, B. Y., Şimşek, C., & Aksoy, S. (2020) · Future Oncology · doi:10.2217/fon-2019-0783 · Cited by 25
Liu, J., Chen, Z., Zhao, P., & Li, W. (2020) · Bioscience Reports · doi:10.1042/bsr20201384 · Cited by 25
Yamada, K., Hazama, S., Suzuki, N., Xu, M. Q., Nakagami, Y., Fujiwara, N., Tsunedomi, R., Yoshida, S., Tomochika, S., Matsukuma, S., et al. (2020) · Oncology Letters · doi:10.3892/ol.2020.12271 · Cited by 25
Taı̈eb, J., André, T., Hajbi, F. E., Barbier, E., Toullec, C., Kim, S. C. H., Bouché, O., Fiore, F. D., Chauvenet, M., Perrier, H., et al. (2020) · Digestive and Liver Disease · doi:10.1016/j.dld.2020.11.031 · Cited by 25
Self-citationStromal Protein-Mediated Immune Regulation in Digestive Cancers
Gamradt, P., de la Fouchardière, C., & Hennino, A. (2021) · Cancers · doi:10.3390/cancers13010146 · Cited by 27
Taiwan Society of Colon and Rectal Surgeons Consensus on mCRC Treatment
Chen, H., Ke, T., Huang, C., Jiang, J.-K., Chen, C., Hsieh, Y., Teng, H., Lin, B., Liang, Y., Su, Y., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.764912 · Cited by 24
Ciardiello, D., Famiglietti, V., Napolitano, S., Esposito, L., Pietrantonio, F., Avallone, A., Maiello, E., Cremolini, C., Troiani, T., Martinelli, E., et al. (2022) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2022.01.005 · Cited by 29
Emerging actionable targets to treat therapy-resistant colorectal cancers
Grassilli, E., & Cerrito, M. G. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2021.96 · Cited by 26
Regulation, genomics, and clinical characteristics of cuproptosis regulators in pan-cancer
Zhou, C., Li, C., Zheng, Y., & Huang, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.934076 · Cited by 24
Cabezón‐Gutiérrez, L., Custodio‐Cabello, S., Palka-Kotlowska, M., Díaz-Pérez, D., Mateos-Domínguez, M., & Jara, P. G. (2022) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2022.10.018 · Cited by 26
Challenges and exploration for immunotherapies targeting cold colorectal cancer
Li, D., Tang, Y., & Wang, X. (2023) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v15.i1.55 · Cited by 27
Martinelli, E., Arnold, D., Cervantes, A. M. R., Stintzing, S., Cutsem, E. V., Tabernero, J. M., Taı̈eb, J., Wasan, H. S., & Ciardiello, F. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102541 · Cited by 25
Mo, S.-F., Cai, Z.-Z., Kuai, W.-H., Li, X., & Chen, Y. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1209243 · Cited by 31
Horiuchi, K., Ikemura, S., Sato, T., Shimozaki, K., Okamori, S., Yamada, Y., Yokoyama, Y., Hashimoto, M., Jinzaki, M., Hirai, I., et al. (2023) · The Oncologist · doi:10.1093/oncolo/oyad187 · Cited by 25
Takehara, Y., Nagasaka, T., Nyuya, A., Haruma, T., Haraga, J., Mori, Y., Nakamura, K., Fujiwara, T., Boland, C. R., & Goel, A. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-017-1376-4 · Cited by 28
Challenges and Opportunities for Childhood Cancer Drug Development
Houghton, P. J., & Kurmasheva, R. T. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.016972 · Cited by 25
Stein, M. K., Williard, F. W., Xiu, J., Tsao, M. W., Martin, M. G., Deschner, B. W., Dickson, P. V., Glazer, E. S., Yakoub, D., Shibata, D., et al. (2020) · Journal of Surgical Oncology · doi:10.1002/jso.25899 · Cited by 25
Self-citationOrganoid in colorectal cancer: progress and challenges
Ji, D., & Wu, A. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000882 · Cited by 26
Grant, M. J., DeVito, N., & Salama, A. K. S. (2018) · Melanoma Management · doi:10.2217/mmt-2018-0004 · Cited by 24
SIRPα blockade improves the antitumor immunity of radiotherapy in colorectal cancer
Ji, K., Zhang, Y., Jiang, S., Sun, L., Zhang, B., Hu, D., Wang, J., Zhao, L., Wang, P., & Tao, Z. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01472-4 · Cited by 24
Update on the management of elderly patients with colorectal cancer
Soler, G., Valera, J. S., Viana-Alonso, A., Urtasún, J. A., García-Escobar, I., Gómez‐España, M. A., Guillén‐Ponce, C., Molina-Garrido, M. J., & Sarrió, R. G. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03243-0 · Cited by 28
Han, Y.-J., Shao, C.-Y., Yao, Y., Zhang, Z., Fang, M., Gong, T., Zhang, Y., & Li, M. (2023) · Postgraduate Medical Journal · doi:10.1093/postmj/qgad136 · Cited by 26
Colorectal cancer with BRAF V600E mutation: Trends in immune checkpoint inhibitor treatment
Liu, M., Liu, Q., Hu, K., Dong, Y., Sun, X., Zou, Z., Ji, D., Liu, T., & Yu, Y. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104497 · Cited by 24
Immunotherapeutic advances in gastrointestinal malignancies
Rao, D., Parakrama, R. Y., Augustine, T. A., Liu, Q., Goel, S., & Maitra, R. (2019) · npj Precision Oncology · doi:10.1038/s41698-018-0076-8 · Cited by 25
WRN-Mutated Colorectal Cancer Is Characterized by a Distinct Genetic Phenotype
Zimmer, K., Puccini, A., Xiu, J., Baca, Y., Spizzo, G., Lenz, H., Battaglin, F., Goldberg, R. M., Grothey, A. F., Shields, A. F., et al. (2020) · Cancers · doi:10.3390/cancers12051319 · Cited by 24
Self-citationRefractory Metastatic Colorectal Cancer: Current Challenges and Future Prospects
Lam, M., Lum, C., Latham, S., Smith, S. T., Prenen, H., & Segelov, E. (2020) · Cancer Management and Research · doi:10.2147/cmar.s213236 · Cited by 26
Li, J., Wei, Q., Wu, X., Sima, J., Xu, Q., Wu, M., Wang, F., Mou, H., Hu, H., Zhao, J., et al. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.118 · Cited by 24
Metadata
- Authors
- Overman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., Goldberg, M. V., Cao, Z. A., Ledeine, J.-M., Maglinte, G. A., Kopetz, S., & André, T.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Cancer Trials Ireland (IE)
- Allina Health (US)
- Istituto Oncologico Veneto (IT)
- USC Norris Comprehensive Cancer Center (US)
- Duke Medical Center (US)
- The Royal Melbourne Hospital (AU)
- Bristol-Myers Squibb (United States) (US)
- Bristol-Myers Squibb (Belgium) (BE)
- Sorbonne Université (FR)
- Corresponding author
- Overman, Michael J
- ORCID
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2017-09
- Volume
- 18
- Issue
- 9
- Pages
- 1182-1191
- ISSN
- 1470-2045 (ISSN-L)
- PMC
- PMC6207072
- OpenAlex
- W2739132742
- Cited by
- 2,836
- References
- 37
- Citations by year
- 2026: 185 · 2025: 242 · 2024: 302 · 2023: 382 · 2022: 377 · 2021: 438 · 2020: 361 · 2019: 288 · 2018: 223 · 2017: 31
- FWCI
- 108.88
- Type
- journal article
- Language
- en
- Update notices
- erratum (2017-09-01)
- Open access
- green
- europepmc.org
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Health Research Board (ICORG-2016-1)
- National Institutes of Health (UL1TR000371)
- National Cancer Institute (P30CA016672)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- nivolumab, metastatic colorectal cancer, mismatch repair deficiency, microsatellite instability-high, PD-1 inhibitors, immune checkpoint blockade, objective response rate, disease control rate, progression-free survival, overall survival, treatment toxicity, first-line therapy, second-line therapy, third-line therapy, neoantigens, tumor-infiltrating lymphocytes
- MeSH terms
- Nivolumab, Adult, Antibodies, Monoclonal, Antineoplastic Agents, Carcinoma, Female, Humans, Male, Middle Aged, Colorectal Neoplasms, Treatment Outcome, Disease-Free Survival, Microsatellite Instability, DNA Mismatch Repair, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
